Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (47)

2023

  1. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors

    European Journal of Hospital Pharmacy

  2. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  3. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

  4. Possible heart failure caused by osimertinib in a lung cancer patient

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 4, pp. 1015-1020

2022

  1. A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

    Frontiers in Oncology, Vol. 12

  2. A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital

    Frontiers in Public Health, Vol. 10

  3. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13

  4. Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 12, pp. 2020-2029

  5. Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

    International Journal of Hematology, Vol. 115, Núm. 1, pp. 61-68

  6. Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey

    Journal of medical Internet research, Vol. 24, Núm. 9, pp. e37445

  7. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

    Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119

  8. Patient-reported outcomes y aplicaciones móviles. Revisión de su impacto en los resultados en salud de los pacientes

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 3, pp. 173-181

  9. Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

    Journal of Oncology Pharmacy Practice, Vol. 28, Núm. 5, pp. 1259-1263

  10. Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

    Frontiers in Oncology, Vol. 12

  11. Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease

    Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 4, pp. 548-551

  12. The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search

    Journal of Medical Internet Research, Vol. 24, Núm. 3

2021

  1. Acute pancreatitis in a patient treated with imatinib and gefitinib

    Journal of Oncology Pharmacy Practice, Vol. 27, Núm. 4, pp. 980-983

  2. Aggressiveness of end-of-life cancer care: what happens in clinical practice?

    Supportive Care in Cancer, Vol. 29, Núm. 6, pp. 3121-3127

  3. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

    Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681

  4. COVID-19 in hospitalised patients in Spain: a cohort study in Madrid

    International Journal of Antimicrobial Agents, Vol. 57, Núm. 2